-
-
-
-
-
-
-
Canaccord Reiterates Buy Rating on Intellia Therapeutics (NTLA)
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Raised to $30 at Citizens on Data that is 'Major Milestone'
-
-
-
-
-
-
-
Jones Trading Upgrades Intellia Therapeutics (NTLA) to Buy
-
-
-
-
-
-
-
Oppenheimer on Intellia Therapeutics (NTLA): 'We view the resolution of the clinical trial holds for nex-z as relatively fast and favorable'
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) Tops Q4 EPS by 13c
-
-
-
-
-
-
-
Evercore ISI Downgrades Intellia Therapeutics (NTLA) to In Line
-
-
-
-
-
-
-
BofA Securities Downgrades Intellia Therapeutics (NTLA) to Neutral, 'FDA pause lowers contribution from key value driver'
-
458,833 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

